These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 17940125)

  • 1. Effects of thiazolidinediones on bone loss and fracture.
    Murphy CE; Rodgers PT
    Ann Pharmacother; 2007 Dec; 41(12):2014-8. PubMed ID: 17940125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of thiazolidinediones on BMD and osteoporosis.
    McDonough AK; Rosenthal RS; Cao X; Saag KG
    Nat Clin Pract Endocrinol Metab; 2008 Sep; 4(9):507-13. PubMed ID: 18695700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial.
    Gruntmanis U; Fordan S; Ghayee HK; Abdullah SM; See R; Ayers CR; McGuire DK
    Calcif Tissue Int; 2010 May; 86(5):343-9. PubMed ID: 20354684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis.
    Sorocéanu MA; Miao D; Bai XY; Su H; Goltzman D; Karaplis AC
    J Endocrinol; 2004 Oct; 183(1):203-16. PubMed ID: 15525588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: a 2-year follow-up study.
    Berberoglu Z; Yazici AC; Demirag NG
    Clin Endocrinol (Oxf); 2010 Sep; 73(3):305-12. PubMed ID: 20148906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Thiazolidinediones and skeletal health].
    Meier C; Bodmer M; Meier CR; Kraenzlin ME
    Rev Med Suisse; 2009 Jun; 5(207):1309-10, 1312-3. PubMed ID: 19626930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thiazolidinediones and fractures in men and women.
    Dormuth CR; Carney G; Carleton B; Bassett K; Wright JM
    Arch Intern Med; 2009 Aug; 169(15):1395-402. PubMed ID: 19667303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis.
    Koufany M; Moulin D; Bianchi A; Muresan M; Sebillaud S; Netter P; Weryha G; Jouzeau JY
    Arthritis Res Ther; 2008; 10(1):R6. PubMed ID: 18199331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiazolidinedione-induced skeletal fragility--mechanisms and implications.
    Grey A
    Diabetes Obes Metab; 2009 Apr; 11(4):275-84. PubMed ID: 18671797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of thiazolidinediones and fracture risk.
    Meier C; Kraenzlin ME; Bodmer M; Jick SS; Jick H; Meier CR
    Arch Intern Med; 2008 Apr; 168(8):820-5. PubMed ID: 18443256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin A intake and osteoporosis: a clinical review.
    Crandall C
    J Womens Health (Larchmt); 2004 Oct; 13(8):939-53. PubMed ID: 15671709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).
    Kahn SE; Zinman B; Lachin JM; Haffner SM; Herman WH; Holman RR; Kravitz BG; Yu D; Heise MA; Aftring RP; Viberti G;
    Diabetes Care; 2008 May; 31(5):845-51. PubMed ID: 18223031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone metabolism in type 2 diabetes and role of thiazolidinediones.
    Vestergaard P
    Curr Opin Endocrinol Diabetes Obes; 2009 Apr; 16(2):125-31. PubMed ID: 19300092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Overview: derangement of bone metabolism in diabetes mellitus].
    Takeuchi Y
    Clin Calcium; 2009 Sep; 19(9):1247-55. PubMed ID: 19721195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distal upper and lower limb fractures associated with thiazolidinedione use.
    Jones SG; Momin SR; Good MW; Shea TK; Patric K
    Am J Manag Care; 2009 Aug; 15(8):491-6. PubMed ID: 19670952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials.
    Zhu ZN; Jiang YF; Ding T
    Bone; 2014 Nov; 68():115-23. PubMed ID: 25173606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes.
    Aubert RE; Herrera V; Chen W; Haffner SM; Pendergrass M
    Diabetes Obes Metab; 2010 Aug; 12(8):716-21. PubMed ID: 20590749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial.
    Grey A; Bolland M; Gamble G; Wattie D; Horne A; Davidson J; Reid IR
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1305-10. PubMed ID: 17264176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical risk factors for fracture in postmenopausal osteoporotic women: a review of the recent literature.
    LaFleur J; McAdam-Marx C; Kirkness C; Brixner DI
    Ann Pharmacother; 2008 Mar; 42(3):375-86. PubMed ID: 18230704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.